MARKET

ALT

ALT

Altimmune
NASDAQ
6.91
+0.02
+0.29%
After Hours: 6.82 -0.09 -1.30% 19:24 04/19 EDT
OPEN
6.85
PREV CLOSE
6.89
HIGH
7.01
LOW
6.64
VOLUME
3.59M
TURNOVER
0
52 WEEK HIGH
14.84
52 WEEK LOW
2.090
MARKET CAP
489.89M
P/E (TTM)
-4.1599
1D
5D
1M
3M
1Y
5Y
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
Recent trial data from Viking Therapeutics could make it a potential acquisition target for Pfizer. The GLP-1 weight loss market is projected to grow to $100 billion by 2030. Novo Nordisk and Eli Lilly are the leaders in the space. Pfizer makes logical sense in a potential deal for Viking. The company recently completed a successful Phase 2 trial of its drug in the obesity treatment.
Seeking Alpha · 4d ago
Weekly Report: what happened at ALT last week (0408-0412)?
Weekly Report · 4d ago
Buy Altimmune's Potential Market Disruption With Pemvidutide
Altimmune, Inc. Is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Its lead drug candidate, Pemvidutide, has shown promising results in clinical trials for obesity. The drug candidate targets glucagon-like peptide 1 and glucagon receptors to produce weight loss with reduced side effects. ALT is a viable investment for investors who are aware of the risks in biotech.
Seeking Alpha · 04/12 16:02
How Is The Market Feeling About Altimmune?
Altimmune's short percent of float has risen 15.72% since its last report. The company has 12.51 million shares sold short, which is 17.81% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/08 13:00
Weekly Report: what happened at ALT last week (0401-0405)?
Weekly Report · 04/08 10:40
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
3 analysts have maintained Buy ratings on Roivant Sciences, Terns Pharmaceuticals and Altimmune. The Healthcare sector is a hot area for insiders to make moves following their insider activities. The analysts maintain bullish sentiments on all 3 stocks in a report released today. Roivant sciences, terns pharmaceuticals and altimmune are all in the healthcare sector.
TipRanks · 04/03 12:11
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Biomea Fusion, BlackRock, Capital Bancorp and 3M among companies. JP Morgan raises target price to $767 from $742 for BlackRock. 3M Co, Advance Auto Parts and AIG among companies with target price cuts.
Reuters · 04/02 07:59
ALTIMMUNE INC <ALT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $12 FROM $15
Reuters · 04/02 04:16
More
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.